


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **linagliptin** (DPP-4 inhibitors)
- Comparator (class): **canagliflozin** (SGLT2 Inhibitors)
- Outcome: **Thyroid tumor**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	127,176	105,483	123	1.17
Merative CCAE	4,793	3,523	6	1.70
Merative MDCD	2,654	1,818	<5	<2.75
Merative MDCR	1,490	1,474	<5	<3.39
Optum Clinformatics	11,462	9,164	16	1.75
Optum EHR	5,438	1,138	<5	<4.39
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

